January 26, 2021
11:00 am - 11:15 am
EST
Opening Remarks
11:15 am - 11:45 am
EST
Keynote Address: Addressing Toxicity via Next-Gen Combinatory CAR-T Therapies
Cameron Durrant MD -
CEO,
Humanigen
Gain insight into technology-enabled combination CAR-T treatments currently being explored to break the efficacy/toxicity linkage. How can industry engage novel clinical collaborations to advance next gen CAR-T therapies for significant unmet need?
11:45 am - 12:00 pm
EST
Q&A Session
12:00 pm - 12:30 pm
EST
Advancing Clinical Efficacy in the Solid Tumor Space
Steve Kanner -
CSO,
Caribou Biosciences
James Trager - CSO, Nkarta Therapeutics
Take a look at the current landscape for novel gene editing technologies to enhance T cell function, including the role of collaboration and partnerships in developing new CAR T therapies for solid tumors and broader cancer indications.
12:30 pm - 12:45 pm
EST
Q&A Session
12:45 pm - 1:15 pm
EST
Breaking Through with CarT & The Next Generation of Therapies
Yan Chen -
President & CEO,
Elpis Biopharmaceuticals
Chris Heery MD - CMO, Precision Biosciences
Paul Rennert - CSO, Aleta BioTherapeutics
What will it take to carry the next generation of therapy through to broader cancer indications? Analyze existing clinical data and solution-driven strategies. Explore the landscape for Allo vs Auto approaches, and how to best address the clinical and commercial challenges faced by patient specific therapies. How can industry navigate a very transitional landscape and what is the impact of operating in a rapidly changing environment?
1:15 pm - 1:30 pm
EST
Q&A Session
1:30 pm - 2:00 pm
EST
Virtual Speed Networking with ULS
End your virtual forum experience for the day with 3 minute networking sessions with groups of 4 people at a time, at the end of 3 minutes, you are "pushed" into another room and meet 3 new people.
